Search Within

Department of Medicine

Formats
  1. Journal Article (19572)
  2. Meeting Abstract (16038)
  3. Review (1147)
  4. Book Section (934)
  5. Editorial (607)
  6. Research Letter (314)
  7. Conference Paper (301)
  8. Guidelines (295)
  9. Correspondence (235)
  10. Miscellaneous (90)
  11. Book Whole (61)
Groups
  1. Solid Tumor Oncology Division (22311)
  2. Hematologic Malignancies, Division of (13264)
  3. Center for Hematologic Malignancies (11049)
  4. GSK Faculty (10640)
  5. Survivorship Research (9323)
  6. Division of Subspecialty Medicine (7531)

More Groups

People
  1. Robert Motzer (1248)
  2. Howard Scher (1132)
  3. Sergio Giralt (1068)
  4. Miguel-Angel Perales (943)
  5. Clifford Hudis (905)
  6. Jedd Wolchok (905)

More People

Years
  1. 2025 (1043)
  2. 2024 (2291)
  3. 2023 (2452)
  4. 2022 (2621)
  5. 2021 (2534)
  6. 2020 (2563)

More Years

Publications
  1. Journal of Clinical Oncology (6125)
  2. Blood (3721)
  3. Annals of Oncology (1398)
  4. Cancer Research (1238)
  5. Clinical Cancer Research (902)
  6. Biology of Blood and Marrow Transplantation (679)

More Publications

Publishers
  1. American Society of Clinical Oncology (6456)
  2. Elsevier Inc. (4213)
  3. American Society of Hematology (4000)
  4. American Association for Cancer Research (2896)
  5. Oxford University Press (2286)
  6. Nature Publishing Group (2109)

More Publishers

Results (39594)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Effect of post-discharge symptom monitoring on hospital readmissions: A randomized trial
    Meeting Abstract

    Daly, R. M.; Mao, J. J.; Cracchiolo, J. R.; Holland, J. C.; Huang, J.; Ebstein, A. M.; Walters, C.; Ackerman, J.; Raj, N. P.; Sanford, R. A.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Use of a large language model (LLM) for pan-cancer automated detection of anti-cancer therapy toxicities and translational toxicity research
    Meeting Abstract

    Bakouny, Z.; Ahmed, N.; Fong, C.; Rahman, A.; Perea-Chamblee, T.; Pichotta, K.; Waters, M.; Fu, C.; Jeng, M. Y.; Lee, M.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Treatment patterns, genomic characteristics, and outcomes among patients with metastatic lobular breast cancer
    Meeting Abstract

    Shen, S.; Pareja, F.; White, C.; Chen, Y.; Safonov, A.; Razavi, P.; Dang, C. T.; Jhaveri, K. L.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Ultrasensitive ctDNA monitoring during CDK4/6 inhibitor therapy for metastatic breast cancer
    Meeting Abstract

    Ah-Reum An, J.; Jasper, J.; Cabel, L.; Yildirim, S. Y.; da Silva, E. M.; Patel, R. K.; LaBella, M.; Teysir, J.; Mai, N.; Safonov, A.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Effect of ERBB2 activating mutations on enhanced internalization and activity of trastuzumab deruxtecan in HER2-non-amplified metastatic breast cancer
    Meeting Abstract

    Mai, N.; Liu, B.; Safonov, A.; Shen, S.; Zelizer, S.; White, C.; Chen, Y.; Razavi, P.; Jhaveri, K. L.; Modi, S.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Phase 1 trial of exercise as first-line therapy for hormone receptor (HR)–positive advanced breast cancer (TBCRC 054)
    Meeting Abstract

    Iyengar, N. M.; Lavery, J. A.; Carlson, A.; Castillo, V.; Lehman, S.; Michalski, M. G.; Harrison, J.; Braun, A.; Flores, J.; Chun, S.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Treatment patterns in HR+/HER2-metastatic breast cancer (MBC) with co-occurring PIK3CA and ESR1 mutations
    Meeting Abstract

    Teysir, J.; Shen, S.; White, C.; Chen, Y.; Razavi, P.; Jhaveri, K. L.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Updated efficacy of mutant-selective PI3Kα inhibitor RLY-2608 in combination with fulvestrant in patients with PIK3CA-mutant HR+HER2-advanced breast cancer: ReDiscover trial
    Meeting Abstract

    Sammons, S. L.; Manich, C. S.; Italiano, A.; Schram, A. M.; Ortega, P. T.; Schott, A. F.; Guerrero, A.; Aix, S. P.; Nanda, R.; Wisinski, K. B.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Patient-reported outcomes (PROs) in patients with ER+, HER2- advanced breast cancer (ABC) treated with imlunestrant, investigator’s choice standard endocrine therapy, or imlunestrant + abemaciclib: Results from the phase III EMBER-3 trial
    Meeting Abstract

    Curigliano, G.; O'Shaughnessy, J.; Bidard, F. C.; Kim, S. B.; Tokunaga, E.; Aftimos, P. G.; Manich, C. S.; Carey, L. A.; Okera, M.; Melo, É.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • INAVO120: Phase III trial final overall survival (OS) analysis of first-line inavolisib (INAVO)/placebo (PBO) + palbociclib (PALBO) + fulvestrant (FULV) in patients (pts) with PIK3CA-mutated, hormone receptor-positive (HR+), HER2-negative (HER2–), endocrine-resistant advanced breast cancer (aBC)
    Meeting Abstract

    Turner, N. C.; Im, S. A.; Saura, C.; Juric, D.; Loibl, S.; Kalinsky, K.; Schmid, P.; Loi, S.; Thanopoulou, E.; Shankar, N.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save